Status:
TERMINATED
Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer
Lead Sponsor:
University of Michigan Rogel Cancer Center
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The majority pf breast cancers present as ER-positive, many of which are able to be targeted with multiple hormonal therapies. Altering ER-negative tumors to increase ER expression has the potential t...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Women who have Her-2 positive and ER- negative or ER-low breast cancer that has not metastasized, or spread to other parts of the body, are eligible for the study.
- Participants must have had either a core biopsy or incisional biopsy of their breast cancer, but not yet had definitive breast surgery, including lumpectomy or mastectomy.
- Participants may not have had a BRCA mutation found on genetic testing.
- Participants should have not yet received treatment for their breast cancer, including:
- chemotherapy,
- hormonal therapy,
- trastuzumab.
Exclusion
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00726180
Start Date
July 1 2008
End Date
October 1 2010
Last Update
October 15 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States, 48109